Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (12 / 03 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Editorial changes were made to this summary.
Malignant Mesothelioma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular Classification of Small Cell Lung Cancer
Before initiating treatment of a patient with small cell lung cancer (SCLC), an experienced lung cancer pathologist should review the pathologic material.Pathologic ClassificationThe current classification of subtypes of SCLC includes the following:Small cell carcinoma.Combined small cell carcinoma (i.e., SCLC combined with neoplastic squamous and/or glandular components).SCLC arising from neuroendocrine cells forms one extreme of the spectrum of neuroendocrine carcinomas of the lung.Neuroendocrine tumors include the following:Low-grade typical carcinoid.Intermediate-grade atypical carcinoid.High-grade neuroendocrine tumors including large-cell neuroendocrine carcinoma (LCNEC) and SCLC.Because of differences in clinical behavior, therapy, and epidemiology, these tumors are classified separately in the World Health Organization (WHO) revised classification. The variant form of SCLC called mixed small cell/large cell carcinoma was not retained in the revised WHO classification.
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Small Cell Lung Cancer
Recurrent small cell lung cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the chest, central nervous system, or in other parts of the body.
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Lung Cancer Screening
Tests are used to screen for different types of cancer.Some screening tests are used because they have been shown to be helpful both in finding cancers early and decreasing the chance of dying from these cancers. Other tests are used because they have been shown to find cancer in some people; however, it has not been proven in clinical trials that use of these tests will decrease the risk of dying from cancer. Scientists study screening tests to find those with the fewest risks and most benefits. Cancer screening trials also are meant to show whether early detection (finding cancer before it causes symptoms) decreases a person's chance of dying from the disease. For some types of cancer, finding and treating the disease at an early stage may result in a better chance of recovery. Clinical trials that study cancer screening methods are taking place in many parts of the country. Information about ongoing clinical trials is available from the NCI Web site. Three screening tests have been
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Overview
Separate PDQ summaries on Lung Cancer Prevention, Small Cell Lung Cancer Treatment, Non-Small Cell Lung Cancer Treatment, and Levels of Evidence for Cancer Screening and Prevention Studies are also available.Evidence of Benefit Associated With ScreeningScreening by low-dose helical computed tomographyBenefitsThere is evidence that screening persons aged 55 to 74 years who have cigarette smoking histories of 30 or more pack-years and who, if they are former smokers, have quit within the last 15 years reduces lung cancer mortality by 20% and all-cause mortality by 6.7%.Magnitude of Effect: 20% relative reduction in lung cancer–specific mortality. Study Design: Evidence obtained from a randomized controlled trial.Internal Validity: Good.Consistency: Not applicable—one randomized trial to date.External Validity: Fair.HarmsBased on solid evidence, screening would lead to false-positive tests in approximately one-quarter of those screened. Most abnormalities would be monitored
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000062945-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Small Cell Lung Cancer Treatment
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (11 / 02 / 2012)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Changes were made to this summary to match those made to the health professional version.
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Treatment Options by Stage
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Occult Non-Small Cell Lung CancerTreatment of occult non-small cell lung cancer depends on the stage of the disease. Occult tumors are often found at an early stage (the tumor is in the lung only) and sometimes can be cured by surgery.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with occult non-small cell lung cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.Stage 0 (Carcinoma in Situ)Treatment of stage 0 may include the following:Surgery (wedge resection or segmental
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Treatment Option Overview for NSCLC
In NSCLC, results of standard treatment are poor except for the most localized cancers. All newly diagnosed patients with NSCLC are potential candidates for studies evaluating new forms of treatment. Surgery is the most potentially curative therapeutic option for this disease. Postoperative chemotherapy may provide an additional benefit to patients with resected NSCLC. Radiation therapy combined with chemotherapy can produce a cure in a small number of patients and can provide palliation in most patients. Prophylactic cranial irradiation (PCI) may reduce the incidence of brain metastases, but there is no evidence of a survival benefit and the effect of PCI on quality of life is not known.[1,2] In patients with advanced-stage disease, chemotherapy or epidermal growth factor receptor (EGFR) kinase inhibitors offer modest improvements in median survival, though overall survival is poor.[3,4]Chemotherapy has produced short-term improvement in disease-related symptoms in patients with